1. Gene therapy developed to treat autosomal recessive deafness type 9.
2. Utilizes a synthetic adeno-associated virus for gene delivery.
3. 10 participants aged 1.5 to 23.9 years enrolled.
4. Significant hearing improvements observed, especially in ages 5-8.
5. Most gains occurred within the first month post-treatment.
6. Safety profile showed mostly mild to moderate adverse events.
7. Ongoing assessments for long-term effects and durability planned.

Source: nature medicine